Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FZQ02
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,712
Award facts
- Contract value 100% obligated
- $1,712.23 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,712.23 to DMS Pharmaceutical Group Inc. for the supply of Xolair 300 mg/2 mL auto-injector vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will deliver the product to the same location by the ultimate completion date of September 3, 2025. This delivery order was issued without a set-aside designation and is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.999 billion comprehensive pharmaceutical supply agreement valid through November 2026. The SPE2DB contract enables the agency to procure a broad range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through its consistent performance on delivery orders covering diverse medical products ranging from vaccines and injections to specialty oncology treatments and auto-injectors. The company's role under this SPE2DB vehicle includes providing direct pharmaceutical distribution and pharmacy services to military health facilities, leveraging its woman-owned small business status and extensive product portfolio. This particular delivery order for Xolair, a biologic immunosuppressant medication used in the treatment of allergic asthma and chronic urticaria, reflects the company's ongoing support of Department of Defense medical supply requirements across its nationwide healthcare network.
Quick answers
Who was awarded contract SPE2DB25FZQ02?
SPE2DB25FZQ02 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 12, 2025.
How much is contract SPE2DB25FZQ02 worth?
The government has obligated $1,712 on SPE2DB25FZQ02.
Is contract SPE2DB25FZQ02 an order under another contract?
Yes. SPE2DB25FZQ02 is a delivery order under SPE2DB22D9102, an indefinite delivery contract.
Was contract SPE2DB25FZQ02 competed?
The extent of competition for SPE2DB25FZQ02 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award